TY - JOUR
T1 - Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway
AU - Ko, Wen Chin
AU - Chen, Bing Chang
AU - Hsu, Ming Jen
AU - Tsai, Chia Ti
AU - Hong, Chuang Ye
AU - Lin, Chien Huang
PY - 2012/1
Y1 - 2012/1
N2 - Aim:To investigate the signaling pathways involved in thrombin-induced connective tissue growth factor (CTGF) expression in rat vascular smooth muscle cells (VSMCs).Methods:Experiments were preformed on primary rat aortic smooth muscle cells (RASMCs) and a rat VSMC line (A10). CTGF protein levels were measured using Western blotting. Luciferase reporter genes and dominant negative mutants (DNs) were used to investigate the signaling pathways mediating the induction of CTGF expression by thrombin.Results:Thrombin (0.3-3.0 U/mL) caused a concentration-and time-dependent increase in CTGF expression in both RASMCs and A10 cells. Pretreating A10 cells with the protease-activated receptor 1 (PAR-1) antagonist SCH79797 (0.1 μmol/L) significantly blocked thrombin-induced CTGF expression, while the PAR-4 antagonist tcY-NH 2 (30 μmol/L) had no effect. The PAR-1 agonist SFLLRN-NH 2 (300 μmol/L) induced CTGF expression, while the PAR-4 agonist GYPGQV-NH 2 (300 μmol/L) had no effect. Thrombin (1 U/mL) caused time-dependent phosphorylation of c-Jun N-terminal kinase (JNK). Pretreating with the JNK inhibitor SP600125 (3-30 μmol/L) or transfection with DNs of JNK1/2 significantly attenuated thrombin-induced CTGF expression. Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125. The AP-1 inhibitor curcumin (1-10 μmol/L) concentration-dependently attenuated thrombin-induced CTGF expression.Conclusion:Thrombin acts on PAR-1 to activate the JNK signaling pathway, which in turn initiates AP-1 activation and ultimately induces CTGF expression in VSMCs.
AB - Aim:To investigate the signaling pathways involved in thrombin-induced connective tissue growth factor (CTGF) expression in rat vascular smooth muscle cells (VSMCs).Methods:Experiments were preformed on primary rat aortic smooth muscle cells (RASMCs) and a rat VSMC line (A10). CTGF protein levels were measured using Western blotting. Luciferase reporter genes and dominant negative mutants (DNs) were used to investigate the signaling pathways mediating the induction of CTGF expression by thrombin.Results:Thrombin (0.3-3.0 U/mL) caused a concentration-and time-dependent increase in CTGF expression in both RASMCs and A10 cells. Pretreating A10 cells with the protease-activated receptor 1 (PAR-1) antagonist SCH79797 (0.1 μmol/L) significantly blocked thrombin-induced CTGF expression, while the PAR-4 antagonist tcY-NH 2 (30 μmol/L) had no effect. The PAR-1 agonist SFLLRN-NH 2 (300 μmol/L) induced CTGF expression, while the PAR-4 agonist GYPGQV-NH 2 (300 μmol/L) had no effect. Thrombin (1 U/mL) caused time-dependent phosphorylation of c-Jun N-terminal kinase (JNK). Pretreating with the JNK inhibitor SP600125 (3-30 μmol/L) or transfection with DNs of JNK1/2 significantly attenuated thrombin-induced CTGF expression. Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125. The AP-1 inhibitor curcumin (1-10 μmol/L) concentration-dependently attenuated thrombin-induced CTGF expression.Conclusion:Thrombin acts on PAR-1 to activate the JNK signaling pathway, which in turn initiates AP-1 activation and ultimately induces CTGF expression in VSMCs.
KW - activator protein-1 (AP-1)
KW - c-Jun N-terminal kinase (JNK)
KW - connective tissue growth factor
KW - mitogen-activated protein kinase (MAPK)
KW - protease-activated receptor
KW - thrombin
KW - vascular smooth muscle cell
UR - http://www.scopus.com/inward/record.url?scp=84855417970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855417970&partnerID=8YFLogxK
U2 - 10.1038/aps.2011.178
DO - 10.1038/aps.2011.178
M3 - Article
C2 - 22212430
AN - SCOPUS:84855417970
SN - 1671-4083
VL - 33
SP - 49
EP - 56
JO - Acta Pharmacologica Sinica
JF - Acta Pharmacologica Sinica
IS - 1
ER -